Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Apr 10;319(14):1485-1496.
doi: 10.1001/jama.2018.2769.

Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis

Diana M Sobieraj  1 , Erin R Weeda  1 , Elaine Nguyen  1 , Craig I Coleman  1 , C Michael White  1 , Stephen C Lazarus  2 , Kathryn V Blake  3 , Jason E Lang  4 , William L Baker  1
Affiliations
Meta-Analysis

Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis

Diana M Sobieraj et al. JAMA. .

Abstract

Importance: Combined use of inhaled corticosteroids and long-acting β-agonists (LABAs) as the controller and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma.

Objective: To conduct a systematic review and meta-analysis of the effects of SMART in patients with persistent asthma.

Data sources and study selection: The databases of MEDLINE via OVID, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews were searched from database inception through August 2016 and updated through November 28, 2017. Two reviewers selected randomized clinical trials or observational studies evaluating SMART vs inhaled corticosteroids with or without a LABA used as the controller therapy and short-acting β-agonists as the relief therapy for patients aged 5 years or older with persistent asthma and reporting on an outcome of interest.

Data extraction and synthesis: Meta-analyses were conducted using a random-effects model to calculate risk ratios (RRs), risk differences (RDs), and mean differences with corresponding 95% CIs. Citation screening, data abstraction, risk assessment, and strength of evidence grading were completed by 2 independent reviewers.

Main outcomes and measures: Asthma exacerbations.

Results: The analyses included 16 randomized clinical trials (N = 22 748 patients), 15 of which evaluated SMART as a combination therapy with budesonide and formoterol in a dry-powder inhaler. Among patients aged 12 years or older (n = 22 524; mean age, 42 years; 14 634 [65%] were female), SMART was associated with a reduced risk of asthma exacerbations compared with the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.68 [95% CI, 0.58 to 0.80]; RD, -6.4% [95% CI, -10.2% to -2.6%]) and a higher dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.77 [95% CI, 0.60 to 0.98]; RD, -2.8% [95% CI, -5.2% to -0.3%]). Similar results were seen when SMART was compared with inhaled corticosteroids alone as the controller therapy. Among patients aged 4 to 11 years (n = 341; median age, 8 [range, 4-11] years; 69 [31%] were female), SMART was associated with a reduced risk of asthma exacerbations compared with a higher dose of inhaled corticosteroids as the controller therapy (RR, 0.55 [95% CI, 0.32 to 0.94]; RD, -12.0% [95% CI, -22.5% to -1.5%]) or the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.38 [95% CI, 0.23 to 0.63]; RD, -23.2% [95% CI, -33.6% to -12.1%]).

Conclusions and relevance: In this meta-analysis of patients with persistent asthma, the use of single maintenance and reliever therapy compared with inhaled corticosteroids as the controller therapy (with or without a long-acting β-agonist) and short-acting β-agonists as the relief therapy was associated with a lower risk of asthma exacerbations. Evidence for patients aged 4 to 11 years was limited.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Lazarus and Blake reported serving as consultants to the University of Connecticut. Dr Blake also reported receiving institutional grants paid to Nemours Children’s Health System. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Flow Diagram of Literature Search
Figure 2.
Figure 2.. Association of SMART With Exacerbations Requiring Systemic Corticosteroids, Hospitalization, or ED Visits Among Patients Aged 12 Years or Older vs the Same Dose of Inhaled Corticosteroids and LABA Controller Therapy
The box sizes are proportional to study weight and the horizontal lines indicate 95% CIs. The I2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range, 0%-100%), and the P value for heterogeneity is a test of heterogeneity across all studies (P < .10 indicates likely variation across pooled estimates related to statistical heterogeneity). ED indicates emergency department; LABA, long-acting β-agonist; SMART, single maintenance and reliever therapy.
Figure 3.
Figure 3.. Association of SMART With Exacerbations Requiring Systemic Corticosteroids, Hospitalization, or ED Visits Among Patients Aged 12 Years or Older vs a Higher Dose of Inhaled Corticosteroids and LABA Controller Therapy
The box sizes are proportional to study weight and the horizontal lines indicate 95% CIs. The I2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range, 0%-100%), and the P value for heterogeneity is a test of heterogeneity across all studies (P < .10 indicates likely variation across pooled estimates related to statistical heterogeneity). ED indicates emergency department; LABA, long-acting β-agonist; SMART, single maintenance and reliever therapy.
See this image and copyright information in PMC

Comment in

References

    1. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007.
    1. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10(11):2484-2489. - PubMed
    1. European Medicines Agency DuoResp Spiromax. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici.... Accessed January 9, 2018.
    1. Global Initiative for Asthma Global strategy for asthma management and prevention, 2017. http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-managem.... Accessed January 9, 2018.
    1. National Heart, Lung, and Blood Institute Advisory Council Asthma Expert Working Group Needs Assessment Report for Potential Update of the Expert Panel Report-3 (2007): Guidelines for the Diagnosis and Management of Asthma; Bethesda, MD: National Heart, Lung, and Blood Institute; 2015.

Publication types

MeSH terms